Bill would cap drug copies and add inspections for compounding pharmacies

What does this do?

This bill limits compounding pharmacies to making a copy of an already-available commercial drug 20 times per month, unless a patient has a specific medical need for a customized version. It requires yearly federal reports from high-volume compounders shipping across state lines, except hospital pharmacies, and creates mandatory inspections for "large-scale outsourcing facilities" that compound a drug more than 100 times a year. It also lets the FDA set registration fees based on oversight needs instead of a fixed amount.

Who does it affect?

Compounding pharmacies, outsourcing facilities, and physicians who make customized medications, especially high-volume or out-of-state operations, are directly affected. Patients needing special drug forms, such as liquid versions, allergen-free options, or unique dosages, may see changes if their provider must adjust practices to comply.

Why does it matter?

The changes increase oversight and reporting requirements, which could alter how some providers produce or supply compounded medications for patients who depend on them.

What does it cost, and who pays?

• Registration fee no longer fixed at $15,000
• Fee set by FDA oversight funding needs

Where does it stand?